Search Results
Your search for ,NOt matches 22378 pages
Showing 7751 - 7800FDA Issues Alert Regarding SARS-CoV-2 Viral Mutation to Health-Care Providers and Clinical Laboratory Staff
The U.S. Food and Drug Administration (FDA) is alerting clinical laboratory staff and health-care providers that it is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests....
Transmission of Maternal Cancer in Two Infants From Mothers With Cervical Cancer During Delivery
In a brief report published in The New England Journal of Medicine, Arakawa et al described the identification of lung cancer in two children that likely resulted from transmission of maternal cervical cancer tumor cells during vaginal delivery. As noted by the investigators, the transmission of...
Effect of COVID-19 Infection on Cancer Management
In a study reported in JCO Oncology Practice, Wu et al found that almost two-thirds of patients undergoing active cancer management who were diagnosed with COVID-19 over a 4-month period in 2020 had significant delays in planned management. Study Details The retrospective study involved data on...
Analysis of Cardiac Data Among Patients Treated With Osimertinib
As reported in the Journal of Clinical Oncology by Michael S. Ewer, MD, JD, PhD, and colleagues, an analysis of data from clinical trials of osimertinib suggests the absence of a “causal relationship” between osimertinib and cardiac failure. Study Details The study involved a post hoc assessment of ...
FDA Pipeline: Two Reviews in NSCLC, Plus Prescribing Information Update for Darolutamide
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to lorlatinib in ALK-positive non–small cell lung cancer (NSCLC) and Breakthrough Therapy designation to the combination of tiragolumab plus atezolizumab in NSCLC with high PD-L1 expression. The FDA also updated the...
Immune Response to COVID-19 Reduced in Patients With Hematologic Malignancies vs Solid Tumors
Patients with hematologic malignancies varied in their immune response to COVID-19, and some struggled to clear the infection, according to new research published by Abdul-Jawad in Cancer Cell. In contrast, most patients with solid tumors—even those with advanced cancer—were shown to be able to...
Invasive Diagnostic Procedure Complication Rates After Lung Cancer Screening
In a study reported in a research letter in JAMA Network Open, Zhao et al found that the rate of complications from invasive diagnostic procedures after low-dose computed tomography (CT) lung cancer screening in the community setting was lower than a prior estimate—but still higher than reported in ...
Total Neoadjuvant Therapy vs Standard Therapy for Locally Advanced Rectal Cancer
In a systematic review and meta-analysis reported in JAMA Network Open, Kasi et al found that total neoadjuvant therapy was associated with improved pathologic complete response rates vs standard therapy with neoadjuvant concurrent chemoradiotherapy plus adjuvant chemotherapy in patients with...
Three vs Four Courses of Chemotherapy in Younger Patients With AML
As reported in the Journal of Clinical Oncology by Burnett et al, findings from the phase III MRC AML17 trial indicated that four courses of chemotherapy, compared to three courses, reduced the cumulative incidence of relapse and improved relapse-free survival, but not overall survival, in younger...
Facebook Posts and the Spread of Incorrect Information About Perceived Risks of HPV Vaccination
The human papillomavirus (HPV) is the most common sexually transmitted infection in the United States, according to the Centers for Disease Control and Prevention (CDC). HPV is associated with health problems—including cancers—but a vaccine for the virus has been available since 2006. The CDC...
Does Anticancer Therapy Impact Unplanned Hospital Care in Patients With NSCLC?
In a single-institution study reported in JCO Oncology Practice, Shah and Neal found that only a small proportion of unplanned hospital encounters were related to anticancer therapy among patients with non–small cell lung cancer (NSCLC), with almost one-quarter of such encounters being considered...
New Study Explores the Use of Focused Ultradeep DNA Sequencing to Quantify Skin Cancer Risk
Recent research has shed new light on the carcinogenic effect of exposure to ultraviolet (UV) radiation, laying the groundwork for improvements in skin cancer risk stratification and prevention. A study published by Lei Wei, PhD, and colleagues in Science Advances detailed a method to measure the...
Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer
Many patients with prostate cancer are treated with androgen-deprivation therapy. However, patients receiving androgen-deprivation therapy often experience higher levels of fatigue, depression, and cognitive impairment. In a new study published by Hoogland et al in the journal Cancer, researchers...
Adjuvant Gefitinib vs Vinorelbine/Cisplatin in Stage II–IIIA EGFR-Mutant NSCLC: Final Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Zhong et al, the final overall survival results of the phase III CTONG1104 trial indicated no significant advantage of adjuvant gefitinib vs vinorelbine/cisplatin in patients with EGFR-mutant stage II–IIIA (N1–2) non–small cell lung cancer ...
Outcomes After Neoadjuvant Carboplatin/Paclitaxel in Women With Ovarian Cancer and Planned Delayed Surgery: ICON8 Analysis
In a post hoc analysis from the ICON8 trial reported in The Lancet Oncology, Morgan et al found evidence indicating that the evaluation of response to platinum-based neoadjuvant therapy in women with ovarian carcinoma using Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, should...
Tycel J. Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib
Tycel J. Phillips, MD, of the University of Michigan Rogel Cancer Center, discusses phase II data from the CITADEL-204 study, showing that patients with relapsed or refractory marginal zone lymphoma who were not previously treated with a Bruton’s tyrosine kinase inhibitor achieved rapid and durable ...
Multiancestry Meta-analysis of Prostate Cancer Genetics
A research team has published findings from a study that brought together data from genomic prostate cancer studies. Including more than 200,000 men of European, African, Asian, and Hispanic ancestry from around the world, the study is reportedly the largest, most diverse genetic analysis ever...
Feasibility Study of Radical Cystectomy vs Intravesical BCG for High-Grade, Non–Muscle Invasive Bladder Cancer
As reported in the Journal of Clinical Oncology by Catto et al, the BRAVO-Feasibility study showed that recruitment of patients with high-grade, non–muscle invasive bladder cancer into a randomized trial comparing radical cystectomy vs intravesical bacillus Calmette-Guérin (BCG) proved difficult,...
SARS-CoV-2 Infection Among Patients in Italy Undergoing Active Cancer Treatment
In a retrospective study reported as a research letter in JAMA Oncology, Aschele et al found that the incidence of SARS-CoV-2 infection was 0.68% among a large population of patients receiving anticancer treatment in Italy over an approximately 3.5-month period in 2020. Study Details The study...
Use of a Novel CAR T-Cell Therapy in Pediatric and Adult Patients With Advanced B-Cell ALL
Pooled results of two phase I studies, reported in The Lancet by Benjamin et al, indicate that the genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product UCART19 is active and has a manageable toxicity profile in pediatric and adult patients with relapsed...
FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
On January 4, U.S. Food and Drug Administration (FDA) Commissioner Stephen M. Hahn, MD, and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks, MD, PhD, issued the following statement on FDA-authorized dosing schedules for each COVID-19 vaccine. Two different mRNA...
Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer
Surgery, in addition to treatments like chemotherapy and radiation therapy, may improve survival for certain patients with metastatic breast cancer. A research team studied nearly 13,000 patients with stage IV disease and found that those who had surgery in addition to other treatments had a...
Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
Thierry André, MD, and colleagues reported the prospective pooled analysis of six phase III trials in the IDEA collaboration in The Lancet Oncology. The analysis showed that noninferiority in overall survival for 3 vs 6 months of adjuvant chemotherapy was not established in patients with stage III...
Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market
On December 29, Bristol Myers Squibb issued the following statement on nivolumab’s small cell lung cancer (SCLC) indication in the United States. In 2018, nivolumab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCLC whose disease...
Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers
A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...
Ganglioside Vaccine Plus β-Glucan for Patients With High-Risk Neuroblastoma and Prior Disease Progression
In a single-institution phase II study reported in the Journal of Clinical Oncology, Cheung et al found that a subcutaneous ganglioside G2/G3 vaccine plus oral β-glucan produced antibody responses in patients with high-risk neuroblastoma, with higher anti–GD2-IgG1 titers being associated with...
Neoadjuvant Chemotherapy and Overall Survival in Metastatic Endometrial Cancer
In a National Cancer Database analysis reported in JAMA Network Open, Tobias et al found that receipt of neoadjuvant chemotherapy was associated with improved short-term but not long-term survival vs primary debulking surgery in patients with metastatic endometrial cancer. As stated by the...
GLOBOCAN 2020 Database Provides Latest Global Data on Cancer Burden, Cancer Deaths
On December 15, the International Agency for Research on Cancer (IARC) released the latest estimates on the global burden of cancer. The GLOBOCAN 2020 database, accessible online as part of the IARC Global Cancer Observatory, provides estimates of incidence and mortality in 185 countries for 36...
FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine
On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...
Addition of First-Line Pembrolizumab to Chemotherapy in Metastatic Triple-Negative Breast Cancer: KEYNOTE-355
As reported in The Lancet by Javier Cortes, MD, and colleagues, the phase III KEYNOTE-355 trial has shown that the addition of pembrolizumab to chemotherapy improved progression-free survival among previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast...
Gemogenovatucel-T Maintenance in Stage III/IV Ovarian Cancer
In the phase IIb VITAL trial reported in The Lancet Oncology, Rocconi et al found that front-line maintenance with the autologous tumor cell vaccine gemogenovatucel-T did not improve recurrence-free survival vs placebo in patients with stage III/IV ovarian cancer in clinical complete response after ...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
Effect of the COVID-19 Pandemic on Lung Cancer Screening
Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...
Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
In an observational cohort study reported in JAMA Oncology, Catherine H. Van Poznak, MD, FASCO, and colleagues found that the 3-year incidence of osteonecrosis of the jaw was 2.8% among patients with cancer receiving zoledronic acid for metastatic bone disease. Shorter dosing interval, fewer teeth, ...
New Recommendations for Advancing the Scholarly Discipline of Global Oncology
New recommendations aimed at advancing the status of global oncology as an academic discipline were published in November as a special article in JCO Global Oncology.1 The field of global oncology is important. According to the World Health Organization,2 cancer is the second-leading cause of death ...
CMS Increases Access to Telemedicine in Home Health Care
The Centers for Medicare & Medicaid Services (CMS) recently released its Home Health Prospective Payment System final rule for 2021. The final rule reflects comments ASCO submitted on the proposed rule in support of increased access to telemedicine in home health care and concerns over home...
The Heart of Catherine Handy Marshall, MD, MPH’s Work
In 2017, Women Who Conquer Cancer (WWCC) awarded Catherine Handy Marshall, MD, MPH, a Conquer Cancer Young Investigator Award (YIA) grant to explore the impact of cardiovascular disease risk factors on cancer outcomes. Three years after receiving the WWCC YIA, Dr. Handy Marshall is pursuing...
Pembrolizumab Plus Chemotherapy for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer
On November 13, 2020, pembrolizumab (Keytruda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer with tumors expressing PD-L1 (Combined ...
Roswell Park Experts Named to Highly Cited Researchers List
Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020. The list recognizes researchers who have...
Addition of Capivasertib to Docetaxel/Prednisolone in Patients With Metastatic Castration-Resistant Prostate Cancer
In the phase II ProCAID study reported in the Journal of Clinical Oncology, Crabb et al found that the addition of the pan-AKT inhibitor capivasertib to docetaxel and prednisolone did not significantly improve progression-free survival in patients with metastatic castration-resistant prostate...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer
To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...
Pembrolizumab Improves Progression-Free Survival vs Chemotherapy in First-Line Treatment of Microsatellite Instability–High Advanced Colorectal Cancer
As reported in The New England Journal of Medicine by Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues, the second interim analysis of the phase III KEYNOTE-177 trial has shown significantly prolonged progression-free survival with pembrolizumab vs...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...
FDA Approves Adjuvant Osimertinib for EGFR-Mutated NSCLC
On December 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...
European Experts Tackle HPV-Related Cancers
The prevention of infection with the human papillomavirus (HPV), and its related cancers, has become a focus of the European Cancer Organisation. At the group’s 2020 European Cancer Summit, held virtually, members of the organization’s HPV Action Network convened with other experts to share...
Panel on Global Cancer Control Looks for Ways Forward in a War That’s Proving Hard to Win
Are we winning the war on cancer? It’s not so clear, especially with COVID-19 poised to erase recent gains, panelists said at a session on global cancer control at the 2020 European Cancer Summit, which was sponsored by the European Cancer Organisation. “We know what we have to do. My question is...
Addressing Inequality in Cancer Care on a Global Scale
It has become a familiar theme of late: Inequities exist in all aspects of cancer care. Although study after study documents problems with access to care and poorer cancer outcomes among underrepresented groups, less is heard about organized efforts to address these issues. This critical topic was...
IU Simon Researcher Receives $1.3 Million Grant to Improve Breast Cancer Treatment for Black Women
Harikrishna Nakshatri, PhD, who is identifying the unique biology that may make Black women more susceptible to aggressive breast cancer, received a $1.3 million grant from the Department of Defense–Congressionally Directed Medical Research Program’s breast cancer research program. Dr. -Nakshatri...
Intratumoral Injections May Boost Neoadjuvant Response in Resectable Melanoma
Studies reported at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which was held virtually, showed promise for the use of intratumoral injections of novel immunotherapies in treating advanced, resectable melanoma. In the 3-year interim analysis of a global phase II randomized...
